GlaxoSmithKline plc (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 173   

Articles published

GSK 48.47 +0.44 (0.92%)
price chart
Analyst Downgrades: Boston Scientific Corporation, GlaxoSmithKline plc (ADR ...
Analysts are weighing in today on pharmaceutical firms Boston Scientific Corporation (NYSE:BSX) and GlaxoSmithKline plc (ADR) (NYSE:GSK), and big-box retailer Wal-Mart Stores, Inc. (NYSE:WMT). Here's a quick roundup of today's bearish brokerage ...
Related articles »  
GSK Tumbles On Earnings Miss, Lowered EPS Guidance
GlaxoSmithKline plc (ADR) (GSK) reported results for the second quarter of its 2014 fiscal year (2QFY14) today, causing the stock to decline in pre-market trading.
GSK Troubles Extend Beyond China
GlaxoSmithKline plc (ADR) (GSK) once again finds itself in trouble, and this time it is not related to bribery allegations in China.
GSK Gets FDA Approval For Flonase
The global healthcare giant, GlaxoSmithKline plc (ADR) (GSK), announced yesterday that the US Food and Drug Administration (FDA) has approved its allergy relief spray - Flonase - for sale in the US.
Related articles »  
Add Syria To The List: Whistleblower Alleges GSK Corruption
GlaxoSmithKline plc (ADR) (GSK) was again accused for corruption, this time in Syria, after a series of claims in countries from China to Poland had surfaced in the last little while.
Related articles »  
GlaxoSmithKline plc (ADR) (GSK) Announces Quarterly Dividend of $0.65
GlaxoSmithKline plc logo GlaxoSmithKline plc (NYSE:GSK) declared a quarterly dividend on Thursday, July 24th, American Banking News.
Drug Maker on Negative Moves- GlaxoSmithKline plc (ADR) (NYSE:GSK ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) [Trend Analysis] hits intraday high level of $48.98, while after all it dropped -2.96% or -$1.48 to close stocks trading at $48.60 in latest trading session.
Related articles »  
Here' Why Investors Ditched GlaxoSmithKline plc (ADR) (NYSE:GSK) And ...
GlaxoSmithKline plc (ADR) (NYSE:GSK) lost 5.98% on Wednesday after the U.K.'s biggest drugmaker reduced its forecast for the year, as sales of its best-selling asthma drug, Advair, continue to fall.
More Problems For GSK � Investigators Charged By Chinese Officials
GlaxoSmithKline plc's (ADR) (GSK) bribery related problems in China seemed to have become more complicated. It seems now the investigators are being investigated.
Related articles »  
GlaxoSmithKline plc trims 2014 forecast
Unveiling its second quarter results, GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK) said 2014 earnings per share looked set to be broadly similar to last year, compared with its previous forecast for growth of 4-8%.
GSK Q2 Profit Down; Sees FY Core EPS Broadly Similar To Last Year - Quick ...  NASDAQ
Related articles »